200 related articles for article (PubMed ID: 422225)
1. Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation.
Vogt W; Schmidt G; Hinsch B
Immunology; 1979 Jan; 36(1):139-43. PubMed ID: 422225
[TBL] [Abstract][Full Text] [Related]
2. Multiple effects of a diamidine (propamidine) on complement activation.
Vogt W; Hinsch B; Schmidt G; Von Zabern I
Immunology; 1979 Jan; 36(1):131-7. PubMed ID: 422224
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
4. C5 convertase of the alternative complement pathway: covalent linkage between two C3b molecules within the trimolecular complex enzyme.
Kinoshita T; Takata Y; Kozono H; Takeda J; Hong KS; Inoue K
J Immunol; 1988 Dec; 141(11):3895-901. PubMed ID: 3183384
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Naja n. naja and Naja h. haje cobra-venom factors: correlation between binding affinity for the fifth component of complement and mediation of its cleavage.
von Zabern I; Hinsch B; Przyklenk H; Schmidt G; Vogt W
Immunobiology; 1980 Dec; 157(4-5):499-514. PubMed ID: 6905795
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
[TBL] [Abstract][Full Text] [Related]
7. The activation of the C3b feedback cycle with human complement components. I. Through the classical pathway.
Mak LW; Lachmann PJ; Majewski J
Clin Exp Immunol; 1977 Nov; 30(2):200-10. PubMed ID: 606442
[TBL] [Abstract][Full Text] [Related]
8. The interaction of C5 with C3b in free solution: a sufficient condition for cleavage by a fluid phase C3/C5 convertase.
Isenman DE; Podack ER; Cooper NR
J Immunol; 1980 Jan; 124(1):326-31. PubMed ID: 7350230
[TBL] [Abstract][Full Text] [Related]
9. C3 requirements for formation of alternative pathway C5 convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
[TBL] [Abstract][Full Text] [Related]
10. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.
Fries LF; Friedman HM; Cohen GH; Eisenberg RJ; Hammer CH; Frank MM
J Immunol; 1986 Sep; 137(5):1636-41. PubMed ID: 3018078
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
[TBL] [Abstract][Full Text] [Related]
12. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
Kitamura H; Tsuboi M; Nagaki K
Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
[TBL] [Abstract][Full Text] [Related]
13. Role of the C3b-binding site on C4b-binding protein in regulating classical pathway C5 convertase.
Rawal N; Pangburn MK
Mol Immunol; 2007 Feb; 44(6):1105-14. PubMed ID: 16979240
[TBL] [Abstract][Full Text] [Related]
14. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
15. Investigation of the mechanisms of anti-complement activity in Ixodes ricinus ticks.
Lawrie CH; Sim RB; Nuttall PA
Mol Immunol; 2005 Jan; 42(1):31-8. PubMed ID: 15488941
[TBL] [Abstract][Full Text] [Related]
16. [Binding of activated C3b component with complement effector].
Kozlov LV; Rostovtseva LI; Lomaka TS; Sutovskaia NS
Bioorg Khim; 1985 Jun; 11(6):762-8. PubMed ID: 3849970
[TBL] [Abstract][Full Text] [Related]
17. Activation of the fifth and sixth component of the complement system: similarities between C5b6 and C(56)a with respect to lytic enhancement by cell-bound C3b or A2C, and species preferences of target cell.
Hänsch GM; Hammer CH; Mayer MM; Shin ML
J Immunol; 1981 Sep; 127(3):999-1002. PubMed ID: 6911149
[TBL] [Abstract][Full Text] [Related]
18. Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway.
Møller-Kristensen M; Thiel S; Sjöholm A; Matsushita M; Jensenius JC
Int Immunol; 2007 Feb; 19(2):141-9. PubMed ID: 17182967
[TBL] [Abstract][Full Text] [Related]
19. A single arginine to tryptophan interchange at beta-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6. Implications for the location of a C5 binding site in C4.
Ebanks RO; Jaikaran AS; Carroll MC; Anderson MJ; Campbell RD; Isenman DE
J Immunol; 1992 May; 148(9):2803-11. PubMed ID: 1573269
[TBL] [Abstract][Full Text] [Related]
20. Trypsin-activated complex of human factor B with cobra venom factor (CVF), cleaving C3 and C5 and generating a lytic factor for unsensitized guinea pig erythrocytes. I. Generation of the activated complex.
Miyama A; Kato T; Horai S; Yokoo J; Kashiba S
Biken J; 1975 Dec; 18(4):193-204. PubMed ID: 1218074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
